Recently, a phase 1/2a clinical trial met the safety endpoint following unilateral injections of CNS10-NPC-GDNF in the lumbar spinal cord of ALS patients, and maintained GDNF production up to 42 months after transplantation [222]. This evidence concerns the gene GDNF and amyotrophic lateral sclerosis.